Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT06324422 Not yet recruiting - Parkinson's Disease Clinical Trials

Exercise as Treatment of Fatigue in Parkinson´s Disease

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The primary goal of this study is to test whether 12 weeks of high-intensity aerobic exercise can treat fatigue in Parkinsons disease (PD). The study will be a randomized multi-site controlled trial with follow up. Clinically fatigued persons with PD will be allocated to either 12 weeks of high-intensity aerobic exercise or to a waitlist control group receiving high-intensity resistance exercise after 24 weeks of habitual lifestyle (control period). It is hypothesized that persons with PD receiving 12 weeks of high-intensity aerobic exercise will show superior effects on perceived fatigue (i.e., clinical relevant reductions) when compared to the PD control group (primary hypothesis), and that these effects are sustained after 12-weeks of follow up (secondary hypothesis).

NCT ID: NCT06304285 Recruiting - Parkinson's Disease Clinical Trials

A Study Assessing the Effects of Acupuncture in Parkinson's Disease Patients With Chronic Appendicitis

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The incidence of PD is high, and when the disease is serious to a certain extent, the effect of drugs to control symptoms decreases, resulting in a significant reduction in the quality of life of patients. Recent studies have found that these PD symptoms are closely related to the intestine. For several cases of PD syndrome patients complicated with chronic appendicitis, our research group conducted acupuncture on points related to constipation and chronic appendicitis, and found that constipation and related motor symptoms of patients could be significantly improved. Clinical studies have shown that acupuncture also has a certain therapeutic effect on non-motor symptoms of Parkinson's disease, such as anxiety and depression, decreased olfactory function, sleep disorders, constipation, early skeletal muscle pain, cognitive dysfunction, etc., which can delay the progression of the disease and improve the quality of life of patients. Starting from intestinal acupuncture, this project further clarified the role of acupuncture treatment in the comprehensive treatment of PD

NCT ID: NCT06289855 Not yet recruiting - Parkinson's Disease Clinical Trials

Impulse Control Disorder Among Parkinson's Disease Patients

Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about impulse control disorders in Parkinson's disease patients. The main question: it aims to answer: - Detect Relative frequency of impulse control disorder among Parkinson's disease patients - Detect Relation between impulse control disorders, and other non motor and motor symptoms in Parkinson's disease patients, using clinical, neurophysiological and radiological assessment

NCT ID: NCT06239454 Recruiting - Parkinson's Disease Clinical Trials

Interleaving Stimulation Improves Dyskinesia in Parkinson's Disease

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This study is designed as a prospective, randomized, double-blind, controlled study to assess putative differences in the effect of interleaving stimulation and empirical stimulation with regards to post-operation dyskinesia control. The primary objective is to assess putative differences in the effect of interleaving stimulation and empirical stimulation with regards to dyskinesia control.

NCT ID: NCT06232772 Not yet recruiting - Parkinson's Disease Clinical Trials

Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease

Start date: March 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate the detection ability of α-Synuclein Ultrafine Fluorescence Detection Method for body fluids (Such as saliva, urine, cerebrospinal fluid, and blood, etc.) and skin in Parkinson's patients.

NCT ID: NCT06175897 Recruiting - Parkinson's Disease Clinical Trials

Effects of STN DBS on Cognition and Brain Networks in PD Patients Analyzed Based on EEG and fNIRS

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

In recent years, deep brain stimulation (DBS) has become the primary treatment for patients with medically uncontrolled Parkinson's disease (PD). Nevertheless, previous studies have shown that it has been controversial whether DBS-subthal amic nucleus (STN) has facilitated or impaired cognitive function in patients with PD. The etiology of the effect of DBS on the single cognitive domain, executive function, has yet to be clarified. Previous clinical studies in which DBS was performed in patients with PD have been performed under the Stroop effect. TMT (Trail Making Test A and B) cognitive tests and simultaneous acquisition of brain function data by electroencephalograph-functional near-infrared spectroscopy (EEG-fNIRS) have yet to be reported. To investigate the effect of DBS-STN on executive function in PD patients and whether there are differences at baseline, 1-month postoperative (DBS-on), 6 months postoperative follow-up, and 12 months postoperative follow-up. Under the condition of electroencephalograph-functional near-infrared spectroscopy (EEG-fNIRS) bimodal technology fusion, The investigators allow PD patients to operate the test of executive function (Stroop/TMT), real-time monitoring of cranial neurophysiology-oxygenation signals, and explore the changes of the brain function network of PD patients, and hope to achieve the following objectives through objective and scientific-technological means: (1) quantify the cognitive function of PD patients through EEG-fNIRS technology and possible trends of changes; (2) explain whether executive functions differ at the level of brain functional network connectivity between surgical and conservative treatments and whether the differences have interaction effects with treatment duration and treatment modalities, as well as analyze their simple effects; (3) To minimize artificial confounders of short-term learning effects and testers common to previous neurocognitive psychobehavioral tests; (4) To explore the mechanism of DBS on the changes of cortical brain networks in PD patients, to avoid or reduce the interference of surgery on cognitive functions, and to provide a theoretical basis for treating personalized surgical plans.

NCT ID: NCT06175767 Not yet recruiting - Parkinson's Disease Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Start date: July 2024
Phase: Phase 2
Study type: Interventional

A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson's Disease.

NCT ID: NCT06164756 Enrolling by invitation - Depression Clinical Trials

Long Term Follow Up KET-PD

Start date: October 18, 2023
Phase:
Study type: Observational

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

NCT ID: NCT06154356 Recruiting - Parkinson's Disease Clinical Trials

Action Observation and Motor Imagery Therapy in Parkinson's Disease

Start date: December 14, 2023
Phase: N/A
Study type: Interventional

In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been used in rehabilitation programs to increase motor learning in Parkinson's disease (PD). Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror neuron system to facilitate motor re-learning. Mirror neurons are activated during the performance of goal-directed actions, also when observing the same action and visualizing the action in the mind. The aim of this clinical trial is to test whether the application of AO and MI treatment in PD in addition to conventional rehabilitation programs has an additional effect on Balance, Functional Status and Quality of Life.

NCT ID: NCT06145711 Not yet recruiting - Parkinson's Disease Clinical Trials

A Clinical Trial of Parkinson's Disease Treatment by hiPSCs Derived Dopaminergic Neural Precursor Cells

hiPSC-DAP
Start date: November 23, 2023
Phase: N/A
Study type: Interventional

XellSmart Biomedical (Suzhou) Co., Ltd. has closely collaborated with Shanghai East Hospital(East Hospital Affiliated To Tongji University) , using iPSC seed cells, on the development and establishment of a dopaminergic neural precursor cell production system. These iPSC seed cells are sourced from the National Stem Cell Translational Resource Bank in Shanghai East Hospital (East Hospital Affiliated To Tongji University), and the construction of the cell bank is carried out by Shanghai East Hospital. The iPSC seed cell preparation method and testing standards have been certified by National Institutes for Food and Drug Control in China. This study is conducted under collaboration between Shanghai East Hospital and XellSmart Biomedical (Suzhou) Co., Ltd. It is a distinctive stem cell therapy research targeting Parkinson's disease patients, characterized by the following: 1. The first instance in China of using autologous iPSC-derived subtype-specific dopaminergic neural precursor cells for alternative transplantation therapy in Parkinson's disease. 2. Before the initiation of this study, there was only one reported case around the world involving the use of laboratory-grade autologous iPSC-induced dopaminergic neural precursor cells for Parkinson's disease treatment in an American Caucasian individual. Positive preliminary clinical research results were obtained and published in the New England Journal of Medicine in 2020. Since then, no similar studies have been reported. It has great significance to conduct this research. It will fill two critical clinical research gaps in stem cell therapy for Parkinson's disease in the world: 1. The use of clinical-grade autologous iPSCs differentiated into dopaminergic neural cells, and treat Parkinson's disease. 2. Evaluating the safety of using autologous iPSC-differentiated dopaminergic neural cells for Parkinson's disease treatment in individuals of Asian descent or Chinese ethnicity.